Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

- January 29th, 2019

Allakos (NASDAQ:ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results from two additional chronic urticaria cohorts: patients with cholinergic urticaria and symptomatic dermographism (also referred to as dermatographic urticaria). As quoted in the press release: Earlier this month, Allakos reported that 12 … Continued

Allakos (NASDAQ:ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results from two additional chronic urticaria cohorts: patients with cholinergic urticaria and symptomatic dermographism (also referred to as dermatographic urticaria).

As quoted in the press release:

Earlier this month, Allakos reported that 12 of 13 patients (92%) in the Xolair-naïve chronic spontaneous urticaria (CSU) cohort achieved a complete response with AK002. Top-line results for the remaining urticaria cohort, patients with chronic spontaneous urticaria who failed to respond to Xolair, are expected later in the first quarter of 2019.

“We are excited by these data especially since there are no approved treatments for patients with cholinergic urticaria and symptomatic dermographism. Furthermore, the activity observed in patients with CSU and these patient cohorts suggests that AK002 may be used across multiple types of urticaria,” said principal investigator of the study, Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité University in Berlin.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Tags

Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *